Global Leading Market Research Publisher QYResearch announces the release of its latest report “EPA Soft Capsules – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. For cardiologists, primary care physicians, and cardiovascular health investors, the management of elevated triglycerides—a key risk factor for cardiovascular disease—remains a persistent clinical challenge. Traditional lifestyle interventions often fail to achieve adequate triglyceride reduction, while existing pharmacotherapies carry side effect concerns or limited efficacy. Omega-3 fatty acid supplements, widely available over the counter, vary significantly in purity and consistency, leaving patients and clinicians uncertain about optimal formulations. EPA soft capsules address this gap by delivering high-purity, prescription-strength eicosapentaenoic acid (EPA) in a stable, bioavailable oral formulation, demonstrated in large-scale clinical trials to significantly reduce triglycerides and cardiovascular risk. This report delivers a comprehensive strategic assessment of a market poised for steady growth, quantifying the value proposition that is driving adoption across hospital and retail pharmacy channels as the cardiovascular benefits of high-dose EPA become increasingly recognized.
Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global EPA Soft Capsules market, including market size, share, demand, industry development status, and forecasts for the next few years. The global market for EPA Soft Capsules was estimated to be worth US$ 1276 million in 2024 and is forecast to a readjusted size of US$ 1955 million by 2031 with a CAGR of 6.3% during the forecast period 2025-2031. EPA Soft Capsules are oral formulations containing eicosapentaenoic acid (EPA) as the active ingredient. They are primarily used to regulate blood lipids, reduce triglyceride levels, and support cardiovascular health. The soft capsule form offers good stability and bioavailability.
In 2024, global EPA Soft Capsules production reached approximately 1063 million capsules, with an average global market price of around US$1.2 per capsule. A typical single-line production capacity is approximately 50-200 million capsules, with an industry gross profit margin of approximately 25%-40%. The EPA raw material accounts for the largest portion of the cost structure (50%-60%), followed by capsule excipients and packaging materials, labor, and manufacturing costs. The upstream component of EPA soft capsules is the EPA API, with major manufacturers including KD Pharma, BASF, Nisshin, Chempoet, and Novasep. The downstream is pharmaceutical companies, health supplement companies, and retail channels.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5054577/epa-soft-capsules
Market Trajectory: Steady Growth Anchored in Cardiovascular Outcomes Data
The projected 6.3% CAGR reflects a market benefiting from robust clinical evidence supporting high-dose EPA therapy for cardiovascular risk reduction. According to recent data from the American Heart Association and cardiovascular outcome registries, the landmark REDUCE-IT trial demonstrated that icosapent ethyl (high-purity EPA) reduced major adverse cardiovascular events by 25% in statin-treated patients with elevated triglycerides—evidence that has driven inclusion in major cardiovascular guidelines and expanded prescribing.
Several factors are driving market expansion. The growing recognition of residual cardiovascular risk—even in patients achieving LDL cholesterol targets with statins—has created demand for therapies that address additional risk factors including elevated triglycerides. The expansion of generic formulations following patent expiration has improved access and reduced cost, expanding the addressable patient population. Additionally, increasing awareness of the differential benefits of EPA versus DHA in cardiovascular protection has focused clinical attention on EPA-specific formulations.
Dosage Segmentation: 0.5g/Capsule and 1.0g/Capsule
The market’s segmentation by dosage strength—0.5g/Capsule and 1.0g/Capsule—reflects different treatment regimens and patient populations. The 1.0g capsule represents the standard dosage for cardiovascular indication, with the approved therapeutic dose of 4g/day requiring four capsules daily. A case study from a cardiology practice illustrates the clinical approach: patients with established cardiovascular disease or diabetes and triglycerides exceeding 150 mg/dL are prescribed high-dose EPA therapy, with 1.0g capsules enabling convenient once-daily dosing at 4g/day.
Application Segmentation: Hospital Pharmacy and Retail Pharmacy
The hospital pharmacy segment serves patients with established cardiovascular disease, often initiated on EPA therapy following hospitalization for cardiovascular events. Hospital-based prescribing enables close monitoring and ensures appropriate patient selection.
The retail pharmacy segment represents the largest and fastest-growing market, with patients receiving long-term prescriptions for cardiovascular risk management. The availability of generic formulations has expanded retail pharmacy dispensing, improving patient access.
Exclusive Industry Insight: The EPA vs. DHA Differentiation
The defining trend shaping the EPA soft capsule market is the growing clinical recognition of the differential cardiovascular effects of EPA versus DHA. Large-scale clinical trials have demonstrated cardiovascular benefit specifically with high-purity EPA formulations, while formulations combining EPA and DHA have shown inconsistent results. This differentiation has driven prescriber preference for EPA-only formulations for cardiovascular indications.
For strategic decision-makers, the EPA soft capsules market presents a compelling opportunity characterized by steady growth, strong clinical evidence supporting cardiovascular risk reduction, and expanding access through generic availability. The projected expansion from US$ 1.28 billion to US$ 1.96 billion by 2031 reflects a market where clinical efficacy, cost-effectiveness, and patient access will define competitive success.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
